Novo Nordisk A/S is betting Ziylo Ltd.’s glucose-responsive compounds can unlock development of smart insulins that are a step up for diabetes therapy. Unlike the competitors, which mostly act when blood glucose is high, Ziylo’s chemistry can also shut off insulin when glucose levels are low, removing the risk of hypoglycemia.
Novo’s acquisition of the U.K. biotech, announced last week, is evidence the pharma is following through on its commitment to move away from insulins that only offer incremental improvements and focus instead on more disruptive technologies (see ).
Ziylo’s platform is still at an early stage, but Novo thinks it has the potential to achieve a major goal in diabetes -- making a hypoglycemia-proof insulin therapy.
Standard insulin therapies require vigilant attention to dosing. If the molecules persist for too long, they can stimulate excessive glucose uptake into tissues, resulting in dangerously low levels of blood glucose.
Companies have long sought alternatives that take responsibility for avoiding hypoglycemia out of patients’ hands by emulating insulin’s homeostatic regulation, which couples its activity to high blood glucose levels. Such a product could increase safety and convenience, and fine-tune efficacy.
The leading approach involves smart devices, which are closed-loop pumps that continuously monitor glucose and automatically deliver insulin when needed. Drug developers are seeking pharmacological solutions as well, via smart insulins that are intrinsically capable of sensing high glucose. But none of the former,